Barclays lowered the firm’s price target on Rapt Therapeutics (RAPT) to $56 from $58 and keeps an Overweight rating on the shares following the Q3 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- RAPT Therapeutics Advances with Strong Financial Backing
- Rapt Therapeutics shares ‘exceptionally compelling,’ says Clear Street
- Promising Clinical and Financial Developments Drive Buy Rating for RAPT Therapeutics
- Buy Rating for RAPT Therapeutics Driven by Promising Ozureprubart Data and Strategic Growth Plans
- Rapt Therapeutics reports Q3 EPS (65c), consensus (85c)